866-997-4948(US-Canada Toll Free)

Global Biomarker Partnering 2010-2015: Deal trends, players, financials and forecasts

Published By :

Current Partnering

Published Date : May 2015

Category :

Biotechnology

No. of Pages : 908 Pages


The Global Biomarker Partnering 2010-2015: Deal trends, players, financials and forecasts report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.
  • Trends in biomarker partnering deals
  • Biomarker partnering agreement structure
  • Biomarker partnering contract documents
  • Top biomarker deals by value
  • Most active biomarker dealmakers
The Global Biomarker Partnering 2010-2015 report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter biomarker partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors biomarker technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 650 links to online copies of actual biomarker deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The report takes readers through the comprehensive biomarker deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering biomarker partnering deals.

The report presents average financial deal terms values for biomarker deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The middle section of the report explores the leaders in the biomarker partnering field; both the leading deal values and leading players are reported allowing readers to see who is succeeding in this growing market. This chapter also looks at the contributions by the big pharma and big biotech companies of the world in terms of deals made. 

Biomarker Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to biomarker trends and structure of deals entered into by leading companies worldwide.

Global Biomarker Partnering 2010-2015 includes:
  • Trends in biomarker dealmaking in the biopharma industry since 2010
  • Analysis of biomarker deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life biomarker deals
  • Access to several biomarker contract documents
  • The leading biomarker deals by value since 2010
  • Most active biomarker dealmakers since 2010
  • The leading biomarker partnering resources
In Global Biomarker Partnering 2010-2015, the available contracts are listed by:
  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
Each deal title links via weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Biomarker Partnering 2010-2015 report provides comprehensive access to available deals and contract documents for over 650 biomarker deals. Analyzing actual contract agreements allows assessment of the following:
  • What are the precise biomarker rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in biomarker dealmaking
2.1. Introduction
2.2. Biomarker partnering over the years
2.3. Biomarker partnering by deal type
2.4. Biomarker partnering by industry sector
2.5. Biomarker partnering by stage of development
2.6. Biomarker partnering by disease type

Chapter 3 – Average financial deal terms for biomarker partnering
3.1. Introduction
3.2. Disclosed financials terms for biomarker partnering
3.3 Biomarker partnering headline values
3.4 Biomarker upfront payments
3.5 Biomarker milestone payments
3.6 Biomarker royalty rates

Chapter 4 – Leading biomarker deals
4.1. Introduction
4.1. Most active in biomarker partnering
4.2. Top biomarker deals by value
4.3. Big pharma biomarker dealmaking activity
4.4. Big biotech biomarker dealmaking activity

Chapter 5 – Biomarker contracts directory
5.1. Introduction
5.2. Biomarker partnering by company A-Z
5.3. Biomarker partnering stage of development
5.4. Biomarker partnering by deal type

Chapter 6 – Future trends and companies in biomarker deal making
6.1. Introduction
6.2. Future partnering trends predicted for biomarker deals
6.3. Emerging companies to watch in 2015
6.4. Emerging companies dealmaking in 2010-2015
6.5. Emerging company financings in 2010-2015
6.6 Conclusion

Appendices
Introduction
Appendix 1 – Directory of biomarker deals by company A-Z 2010-2015
Appendix 2 – Directory of biomarker deals by stage of development 2010-2015
Appendix 3 – Directory of biomarker deals by deal type 2010-2015
Appendix 4 – Directory of biomarker deals by therapy area 2010-2015
Appendix 5 – The anatomy of biomarker partnering
A.5.1 The anatomy of a biomarker deal
A.5.1.a Case study 1: Arno Therapeutics, Invivis Pharmaceuticals - February 2012
Appendix 6 – Antibody partnering resource center
Online antibody partnering
Biomarker partnering events
Further reading on biomarker dealmaking
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering
Order Form – Reports

List of Chart


Figure 1: Biomarker partnering since 2010
Figure 2: Biomarker partnering by deal type since 2010
Figure 3: Biomarker partnering by industry sector since 2010
Figure 4: Biomarker partnering by stage of development since 2010
Figure 5: Biomarker partnering by disease type since 2010
Figure 6: Biomarker deals with a headline value by year- 2015
Figure 7: Biomarker deals with a headline value by year- 2014
Figure 8: Biomarker deals with a headline value by year- 2013
Figure 9: Biomarker deals with a headline value by year- 2012
Figure 10: Biomarker deals with a headline value by year- 2011
Figure 11: Biomarker deals with a headline value by year- 2010
Figure 12: Summary median upfront value by year, 2010-2015
Figure 13: Biomarker deals with an upfront value by year- 2015
Figure 14: Biomarker deals with an upfront value by year- 2014
Figure 15: Biomarker deals with an upfront value by year- 2013
Figure 16: Biomarker deals with an upfront value by year- 2012
Figure 17: Biomarker deals with an upfront value by year- 2011
Figure 18: Biomarker deals with an upfront value by year- 2010
Figure 19: Summary median upfront value by year, 2010-2015
Figure 20: Biomarker deals with a milestone value by year- 2015
Figure 21: Biomarker deals with a milestone value by year- 2014
Figure 22: Biomarker deals with a milestone value by year- 2013
Figure 23: Biomarker deals with a milestone value by year- 2012
Figure 24: Biomarker deals with a milestone value by year- 2011
Figure 25: Biomarker deals with a milestone value by year- 2010
Figure 26: Biomarker deals with a royalty rate value by year- 2015
Figure 27: Biomarker deals with a royalty rate value by year- 2014
Figure 28: Biomarker deals with a royalty rate value by year- 2013
Figure 29: Biomarker deals with a royalty rate value by year- 2012
Figure 30: Biomarker deals with a royalty rate value by year- 2011
Figure 31: Biomarker deals with a royalty rate value by year- 2010
Figure 32: Summary median royalty rate by year, 2010-2015
Figure 33: Active biomarker dealmaking activity– 2010 to 2015
Figure 34: Top biomarker deals by value since 2010
Figure 35: Big pharma – top 50 – Biomarker deals 2010 to 2015
Figure 36: Big pharma biomarker deal frequency – 2010 to 2015
Figure 37: Big biotech – top 50 – Biomarker deals 2010 to 2015
Figure 38: Big biotech biomarker deal frequency – 2010 to 2015
Figure 39: Components of the typical biomarker deal structure
Figure 40: Online partnering resources
Figure 41: Forthcoming partnering events

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *